U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328737) titled 'One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei' on Dec. 28, 2025.
Brief Summary: The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP).
The main questions it aims to answer are:
* Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session?
* What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxic...